Inaktiver Wert

Andere Sprachen Point Capital Inc Other OTC

Aktien

US73052R1041

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment	23.04.
Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment	23.04.
Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University	10.04.
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic	10.04.
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on January 31, 2023.	05.04.
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.	04.04.
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on January 31, 2023.	25.03.
Silo Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25.03.
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic	20.03.
Silo Pharma, Inc. Exercises Option for Exclusive License Agreement for First-In-Class PTSD and Stress-Induced Anxiety Therapeutic	20.03.
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain	18.03.
Silo Pharma, Inc. Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain	18.03.
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD	28.02.
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery	14.02.
Silo Pharma?s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery	14.02.
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology	01.02.
Silo Pharma, Inc. Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology	01.02.
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study	24.01.
Silo Pharma Announces Positive Results in Alzheimer?s Disease Study	24.01.
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.	09.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Point Capital Inc Other OTC

Aktien

US73052R1041

Andere Sprachen

Filter